Are we on the verge of changing the way we treat cancer?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Are we on the verge of changing the way we treat cancer?
Released on: April 14, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In the UK the majority of cancer research is funded through one funder, Cancer Research UK

    With exclusive rights to over £300 million of cancer research per year Cancer Research Technology is a single commercial gateway to to all of that science, a meeting point between academia and industry

    Keith Blundy, CEO of CRT talks to PharmaVentures CEO, Fintan Walton about some of their recent deals with Teva Oncology, Forma Therapeutics and Medimmune.
  • Summary
  • Transcript
  • Participants
  • Company
In the UK the majority of cancer research is funded through one funder, Cancer Research UK

With exclusive rights to over £300 million of cancer research per year Cancer Research Technology is a single commercial gateway to to all of that science, a meeting point between academia and industry

Keith Blundy, CEO of CRT talks to PharmaVentures CEO, Fintan Walton about some of their recent deals with Teva Oncology, Forma Therapeutics and Medimmune.
In the UK the majority of cancer research is funded through one funder, Cancer Research UK

With exclusive rights to over £300 million of cancer research per year Cancer Research Technology is a single commercial gateway to to all of that science, a meeting point between academia and industry

Keith Blundy, CEO of CRT talks to PharmaVentures CEO, Fintan Walton about some of their recent deals with Teva Oncology, Forma Therapeutics and Medimmune.
Keith Blundy
Cancer Research Technology

Keith Blundy joined CRT in 1998, became COO in 2004 and was appointed CEO in 2007. Since then he has overseen the launch of a £50m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) to bridge the UK funding gap between cancer drug discovery and early treatment development. He has initiated risk sharing discovery alliances with AstraZeneca and Teva (formerly Cephalon), the establishment of CRT Inc in Boston (USA) as a business development arm of CRT and the further globalisation of CRT’s cancer IP development and commercialisation through becoming a partner of Cancer Therapeutics Pty in Melbourne, Australia. After completing a PhD at the John Innes Institute and a post doctoral Fulbright scholarship in the US on the regulation of plant gene expression, he spent 10 years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development. Keith has a BSc and PhD in genetics and an MBA from the London Business School. He was formerly a director of KuDOS Pharmaceuticals Ltd and Mission Therapeutics and currently is on the board of Cytosystems Ltd and Cancer Therapeutics Pty. He is a member of Cancer Research UK’s Scientific Executive Board.
Cancer Research Technology
Cancer Research UK is a cancer research and awareness charity in the United Kingdom, formed on 4 February 2002 by the merger of The Cancer Research Campaign and Imperial Cancer Research Fund.